There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...
JOHANNESBURG, Dec 9 (Reuters) - Efficacy results may not be ready for months from a trial of AstraZeneca and Oxford University's coronavirus vaccine in South Africa, the principal investigator of the ...
AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. | AstraZeneca will have to negotiate what ...
AstraZeneca and Oxford University announced on Monday that they had developed a new Covid-19 vaccine with an efficacy rate of 70 to 90 percent. Trials indicated the vaccine could prevent 70 percent of ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic ...
AstraZeneca AZN announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with ...
CSPC Pharmaceutical Group Ltd (HK:1093) announced a major strategic partnership with AstraZeneca PLC (ST:AZN), marking one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results